After announcing earlier this week the appointment of Andreas Wallnöfer, PhD, MBA, to its Board of Directors, Optigo ...

An expert demonstrates how to safely co-manage AMD and GA using staggered dual-pathway treatment to maintain stability and ...

Bispecific antibody treatments remain a promising treatment for diabetic macular edema (DME), as a new study shows that faricimab was effective and had durable results after a year of real-world ...

Patients maintained a consistent and clinically meaningful reduction in supplemental injections in 6-month intervals following dosing with 4D-150, supporting durable disease control across all ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD) appeared to have no major safety issues or significantly affect either ...

Early response to treatment with anti–vascular endothelial growth factor (VEGF) agents may predict long-term outcomes among patients with diabetic macular edema (DME), a small study suggests. "Our ...

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in ...

Continuing anti-vascular endothelial growth factor (VEGF) therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with ...